Robert Goldman, PhD

Efficacy and Safety of SEP-363856, a Novel Psychotropic Agent with a Non-D2 Mechanism of Action, in the Treatment of Schizophrenia: A 4-Week, Randomized, Placebo-Controlled Trial

Background: SEP-363856 is a novel trace amine associated receptor-1 (TAAR1)/5-HT1A agonist with no dopamine-D2/5-HT2A antagonist activity which has shown efficacy in animal models of psyc...

Antony Loebel , MD;

Justine Kent , MD;

Robert Goldman , PhD;

Hailong Cheng , PhD;

Seth Hopkins , PhD;

Kenneth Koblan , PhD;

11/22/2019

Safety and Effectiveness of Long-term Treatment With Lurasidone in Children and Adolescents With Bipolar Depression: Interim Analysis of a 2-year Open-label Extension Study

Objective: To evaluate the long-term safety and efficacy of lurasidone in children and adolescents with bipolar depression. Methods: Patients (10-17 years) with bipolar depression who co...

Antony Loebel , MD;

Robert Goldman , PhD;

Melissa DelBellow , MD;

Andrei Pikalov , MD, PhD;

Ling Deng , PhD;

Michael Tocco , PhD;

03/01/2019

Efficacy of Lurasidone in Child and Adolescent Patients With Bipolar I Depression and Anxiety: A Post-hoc Analysis

Objective: To evaluate the efficacy of lurasidone in treating pediatric patients with bipolar depression who presented with high levels of anxiety.

Antony Loebel , MD;

Robert Goldman , PhD;

Ling Deng , PhD;

Andrei Pikalov , MD, PhD;

Michael Tocco , PhD;

Mark Owens , DO;

03/01/2019

Long-term Efficacy of Lurasidone in Antipsychotic-Naive vs. Antipsychotic-Exposed Adolescents with Schizophrenia: Post-hoc Analysis of a Two Year, Open-label Study

Background: The aim of this post-hoc analysis was to evaluate the long-term efficacy of lurasidone in antipsychotic-naïve adolescents with schizophrenia.

Robert Goldman , PhD;

Christoph U. Correll , MD;

Andrei Pikalov , MD, PhD;

Michael Tocco , PhD;

Jay Hsu , PhD;

10/08/2020

Efficacy and Safety of Lurasidone in Adolescents with Schizophrenia: Analysis of a 2-year, Open-label Extension Study

Objective: To obtain long-term data on the safety and effectiveness of lurasidone in adolescents with schizophrenia Methods: Adolescents (13-17 years) who completed 6 weeks of double-bli...

Andrei Pikalov , MD, PhD;

Michael Tocco , PhD;

Antony Loebel , MD;

Robert Goldman , PhD;

Ling Deng , PhD;

03/01/2019

Effect of Lurasidone on Manic Symptoms and Treatment-Emergent Mania in Children and Adolescents with Bipolar Depression

Background: The aim of these analyses was to assess the effect of lurasidone on manic symptoms and treatment-emergent (TE) mania in pediatric patients with bipolar depression.

Michael Tocco , PhD;

Robert Goldman , PhD;

Andrei Pikalov , MD, PhD;

Courtney Zeni , PhD;

10/08/2020

Effect of Lurasidone on Cognition in Children and Adolescents With Bipolar Depression: Interim Analysis of a 2-year Open-label Extension Study

Objective: To evaluate the long-term effects of lurasidone on cognition in children and adolescents with bipolar depression.

Ling Deng , PhD;

Katherine Burdick , PhD;

Michael Tocco , PhD;

Antony Loebel , MD;

Robert Goldman , PhD;

03/01/2019

Assessing the Benefit-Risk Ratio of Approved Treatments for Bipolar Depression Using Likelihood to be Helped or Harmed (LHH) Analyses

Background: Four medications are FDA approved for acute bipolar depression: lurasidone (LUR), cariprazine (CAR), quetiapine IR & XR (QUE), and olanzapine-fluoxetine combination (OFC)....

Leslie Citrome , MD;

Robert Goldman , PhD;

Andrei Pikalov , MD, PhD;

Courtney Zeni , PhD;

10/08/2020

Effect of Lurasidone on Cognition in Adolescents With Schizophrenia: Analysis of a 2-year Open-label Extension Study

Objective: To evaluate the short and long-term effects of lurasidone on cognitive performance in adolescents with schizophrenia.

Antony Loebel , MD;

Robert Goldman , PhD;

Ling Deng , PhD;

Philip Harvey , PhD;

Josephine Cucchiaro , PhD;

Michael Tocco , PhD;

03/01/2019

Long-term Efficacy of Lurasidone in Antipsychotic-naïve vs. Antipsychotic-exposed Adolescents With Schizophrenia: Post-hoc Analysis of a Two Year, Open-label Study

Background: Few studies have prospectively evaluated short- or long-term antipsychotic efficacy in treatment-naïve (vs. previously treated) first-episode schizophrenia. The aim of this po...

Robert Goldman , PhD;

Christoph U. Correll , MD;

Michael Tocco , PhD;

Jay Hsu , PhD;

11/22/2019